gms | German Medical Science

21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem
8. Symposium der International Society of Ocular Trauma

Deutsche Gesellschaft für Retinologie
International Society of Ocular Trauma

19.06. - 22.06.2008, Würzburg

Low-dose triamcinolone prolongs the effect of bevacizumab in patients with acute exsudative age related macular degeneration

Meeting Abstract

  • Heinrich Gerding - Olten/Schweiz
  • J. Riese - Olten/Schweiz
  • V. Loukopoulos - Olten/Schweiz
  • C. Meier - Olten/Schweiz
  • M. Timmermann - Olten/Schweiz

Retinologische Gesellschaft. International Society of Ocular Trauma. 21. Jahrestagung der Retinologischen Gesellschaft gemeinsam mit dem 8. Symposium der International Society of Ocular Trauma. Würzburg, 19.-22.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocISOTRG2008V118

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 18. Juni 2008

© 2008 Gerding et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Purpose: It was the aim of this study to compare the efficacy of bevacizumab alone versus a combination of low-dose triamcinolone and bevacizumab in the treatment of acute wet AMD.

Methods: Analysis of visual acuity and OCT-CFT development in two non-randomized successive clinical case series either treated with intravitreal bevacizumab (BEV, 1.25 mg) alone or in combination with simultaneous injection of 2 mg triamcinolone (BEV+T). Only treatment naïve patients were included in this study. Analyzed patient groups (BEV, n=32; BEV+T, n=27) did not present significant differences concerning age and basic disease parameters (age, basic visual acuity, type and size of lesion, and CFT) at study entry. Follow-up examinations were performed at days 1 & 7, month 1, 2 & 3 after injection including best corrected visual acuity (BCVA), IOP, slit lamp examination, binocular funduscopy and OCT. Fluorescence angiography was performed before treatment and after 3 months.

Results: BCVA presented a transient improvement of 0.3 log lines at 4 weeks and was -0.1 log lines below entry at 3 months in BEV. BEV+T resulted in an improvement of visual of acuity of 0.8 log lines at 1 & 2 months and 0.5 at the end of follow-up. CFT was significantly decreased at month 1 & 2 in BEV but no longer at month 3. Significant CFT reduction persisted in BEV+T patients for the whole study period (p < 0.0001). Transient secondary ocular hypertension occurred in 1/32 BEV, and 4/27 BEV+T patients.

Conclusions: Preliminary results of this follow-up study indicate that low-dose intravitreal triamcinolone in addition to bevacizumab is resulting in a prolongation of functional benefit and structural benefit in cases with acute exsudative age related macular degeneration.